Baxter International Inc. (BAX) Stock: Price, Forecast & Analyst Target
Baxter International Inc. (BAX) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $25.39 (-2.94%), as of the Nov 19, 2026 trading session; market cap $13.1B. Expected results Feb 11, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Baxter International Inc. · BAX · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-13: Baxter sells infusion, medication-delivery, surgical, organ-support and connected-care products across hospitals and other care settings. The case now rests on whether recovering operating performance and cash generation can persist while a heavy debt load limits financial flexibility.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Baxter International (BAX)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — a fragile balance sheet underneath; a move to treat with suspicion, not chase. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Surging.
- EPS beat 6 of the last 8 reports
- expected results Feb 11, 2027
- Altman Z 2.43 · Piotroski F 4
Holding back: balance-sheet strain, soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 56 | Fair | |
| 56 | Fair | |
| 56 | Fair | |
| 56 | Fair | |
| 57 | Fair | |
| 57 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $25.39 | |
| Change on the day | -2.94% | |
| 52-week range | $15.73–$30.00 | |
| Market capitalisation | $13.1B | — |
| Price / earnings (trailing) | 8.31 | |
| Shares traded on the day | 4.67M | |
| Beta (volatility vs the S&P 500) | 0.67 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Baxter International (BAX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Baxter International (BAX), and what does it report?
Short answer · as of
Baxter is not simply an instrument maker. Its revenue comes from pharmaceuticals, recurring medical supplies and therapies, capital equipment, connected devices, software and contracted services used across acute care, outpatient facilities and supervised home care.
Research dated 2026-09-13.
The reporting structure separates Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. Medical Products and Therapies contributes the most revenue, making treatment volumes and demand for associated supplies especially important to the consolidated result.
What do the latest results show for Baxter International (BAX)?
Research dated 2026-09-13.
The latest period brought a sequential rise in revenue, gross profit and operating profit, while the company returned to positive net income after a loss. Reported revenue and adjusted earnings also exceeded expectations, extending the improvement seen in the preceding report.
Management attributes the expected continuation of margin recovery to higher volumes, operating leverage, cost-structure actions and the passage of higher-cost inventory through the business. That explanation remains a forward operating claim; the reported improvement establishes progress, but not yet durability.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2.83B | -$46M | -$0.09 (diluted) |
| Q4 FY2025 | $2.97B | -$1.13B | -$2.19 (diluted) |
| Q1 FY2026 | $2.70B | -$15M | -$0.03 (diluted) |
| Q2 FY2026 | $2.96B | $126M | $0.24 (diluted) |
What are the financial strengths and risks for Baxter International (BAX)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
Operating cash flow has remained positive through the latest reported periods, and the cash balance has rebuilt from its earlier low. Capital spending rose sharply in the latest period, however, leaving substantially less cash after investment than the operating cash figure alone suggests.
Debt remains far above cash and short-term investments, producing a sizable net-debt position. Negative trailing profitability and middling distress and quality screens reinforce the risk that any relapse in margins or cash conversion would make the balance sheet more restrictive.
What should you watch next at Baxter International (BAX)?
Short answer · as of
The next earnings report is expected on Feb 11, 2027.
Research dated 2026-09-13.
Watch whether revenue holds near its recent level while gross and operating profit continue to recover. The most useful confirmation would be margin expansion accompanied by stronger cash remaining after capital spending, rather than an earnings improvement that fails to convert into cash.
Management has tied later-year improvement to volume, operating leverage, cost actions and lower pressure from higher-cost inventory. The scheduled earnings release will test that mechanism against analyst expectations, while recent leadership and material-agreement filings deserve attention for any effect on execution.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Baxter International compare with its peers?
Short answer
Baxter International's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Baxter combines pharmaceuticals and disposable therapy products with pumps, monitoring systems, surgical infrastructure, software and services. A narrower device company depends mainly on equipment placements, while Baxter can participate in the treatment itself, the supplies consumed during care and the systems used to coordinate it.
That breadth also couples Baxter to several operating demands at once: hospital procedure activity, medication use, critical-care intensity, equipment purchasing and supply-chain execution. Medical Products and Therapies remains the dominant reported business, so the portfolio is diversified without being evenly balanced.
| Company | Price | Market value | Score |
|---|---|---|---|
| $242.61 Nov 18, 2026 | $34.1B | 95 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $49.63 Nov 19, 2026 | $10.3B | 83 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $84.41 Nov 19, 2026 | $5.06B | 81 5-pillar Nov 18, 2026 | |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $156.24 Nov 19, 2026 | $9.83B | 76 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| Baxter International (BAX) — this page | $25.39 | $13.1B | 57 |
| $60.33 Nov 19, 2026 | $11.5B | 40 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $20.00 – $28.00
- Consensus target
- $23.83
- Median target
- $24.50
Consensus record · Captured .
Measured against a quoted price of $25.39 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 2, 2026
- Transactions
- 3
- Identified insiders
- 3
- Purchases
- 0
- Sales
- 0
- Other transactions
- 3
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BAX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BAX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Baxter International (BAX)?
What Investors Ask About Baxter International (BAX) — Healthcare
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How dependent is Baxter on Medical Products and Therapies?
Medical Products and Therapies is Baxter's largest reported revenue contributor. Performance therefore remains especially sensitive to demand for infusion, nutrition, renal-support and related treatment products, even though pharmaceuticals and healthcare systems broaden the revenue base.
What does Baxter's connected-care portfolio add beyond medical supplies?
Baxter combines patient monitoring and diagnostic technologies with devices, software and communication systems. This gives the company exposure to clinical workflows and hospital technology spending alongside demand for products consumed during treatment.
Why are Baxter's reported earnings volatile despite annual revenue growth?
Annual revenue has risen while net results have moved between substantial profits and losses, showing that sales direction alone has not determined shareholder earnings. Recent periods show operating profitability recovering from a severe loss, but the record remains uneven.
What would validate Baxter's margin expansion plan?
Higher treatment volumes should produce better operating leverage while cost actions and higher-cost inventory pressure recede. Confirmation would appear in sustained gross and operating profit improvement together with healthier cash after capital spending.
What is the BAX stock price today?
The last price recorded for Baxter International Inc. (BAX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BAX price target?
The analyst consensus price target for Baxter International Inc. (BAX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 18 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com